

# Rheumatoid Arthritis Drugs Market | Global Upcoming Trends, Growth Drivers, Opportunities and Challenges

PORTLAND, OR, UNITED STATES, March 24, 2023 /EINPresswire.com/ -- The [Rheumatoid Arthritis Drugs Market](#) is a rapidly growing segment of the pharmaceutical industry. Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes inflammation in the joints, leading to pain, swelling, and stiffness. The global market for RA drugs is expected to grow significantly in the coming years due to the increasing prevalence of the disease, the aging population, and the development of new and effective drugs.



There are several classes of drugs used to treat RA, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers (biologics). The most commonly used DMARDs are methotrexate, sulfasalazine, and hydroxychloroquine, while biologics such as TNF inhibitors, interleukin inhibitors, and B-cell inhibitors are used in more severe cases.

The market for RA drugs is dominated by biologics, which accounted for over 70% of the market share in 2020. This is due to the effectiveness of biologics in treating RA and the high cost of these drugs. However, the market for biosimilars, which are less expensive versions of biologics, is also growing rapidly and is expected to increase competition and reduce prices in the market.

The major players in the RA drugs market include Amgen Inc., UCB S.A., Eli Lilly and Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc. These companies are investing heavily in research and development to develop new and innovative drugs to treat RA and maintain their market position. Additionally, mergers and acquisitions are also common in the RA drugs market, as companies look to expand their product portfolios and geographic reach.

According to the report published by Allied Market Research, the global Rheumatoid Arthritis Drugs Market was estimated at \$57.92 billion in 2019 and is expected to hit \$62.93 billion by 2027, registering a CAGR of 2.8% from 2020 to 2027. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends.

Request a sample of the report: <https://www.alliedmarketresearch.com/request-sample/3753>

Rise in the prevalence of rheumatoid arthritis, surge in geriatric population, and transition from symptom management to slowing the progression of the disease are the major factors that drive the growth of the global rheumatoid arthritis drugs market. On the other hand, side effects associated with the medication and higher cost of biologics & biosimilars restrain the market growth to some extent. Nevertheless, developments in the field of biosimilars and novel biologics are expected to pave the way for new opportunities in the industry.

Download the report: <https://www.alliedmarketresearch.com/download-sample/3753>

The manufacturing of drugs are considered under essential services and thus, the global rheumatoid arthritis drugs market has not been much affected.

Drugs used for treatment of rheumatoid arthritis like tocilizumab and hydroxychloroquine have also been studied for treatment of the novel corona virus.

Check out the report: <https://www.alliedmarketresearch.com/checkout-final/9537febefb39363657e81a202a37364f>

The global rheumatoid arthritis drugs market is analyzed across drug class, administration, sales channel, and region. Based on drug class, the disease-modifying anti-rheumatic drugs segment contributed to nearly four-fifths of the global rheumatoid arthritis drugs market share in 2019 and is projected to retain its dominance throughout the forecast period. The non-steroidal anti-inflammatory drugs segment, on the other hand, is expected to portray the highest CAGR of 3.5% from 2020 to 2027.

The parenteral segment accounted for nearly three-fourths of the global rheumatoid arthritis drugs market revenue in 2019 and is anticipated to rule the roost by 2027. Simultaneously, the oral segment would register the highest CAGR of 3.1% till 2027.

Purchase the report: <https://www.alliedmarketresearch.com/purchase-enquiry/3753>

North America generated the highest in 2019, generating more than two-fourths of the global

rheumatoid arthritis drugs market. At the same time, the Asia-Pacific region would showcase the fastest CAGR of 3.2% by 2027. The other two provinces studied in the report include Europe and LAMEA.

The key market players analyzed in the global rheumatoid arthritis drugs market report include Amgen Inc., UCB S.A., Eli Lilly and Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc. These market players have incorporated several strategies including partnership, expansion, collaboration, joint ventures, and others to brace their stand in the industry.

Infertility Treatment Market Share : <https://www.alliedmarketresearch.com/infertility-treatment-market-A09505>

Branded Generics Market Size : <https://www.alliedmarketresearch.com/branded-generics-market-A10537>

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

5933 NE Win Sivers Drive

#205, Portland, OR 97220

United States

Toll Free: +1-800-792-5285

UK: +44-845-528-1300

Hong Kong: +852-301-84916

help@alliedmarketresearch.com

Web: <https://www.alliedmarketresearch.com>

David Correa

Allied Analytics LLP

+1-800-792-5285

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/624081387>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.